In 2019, more than 12,000 new cases of cervical cancer were diagnosed and upwards of 4,000 patients died in the U.S. The causal link between human papillomavirus (HPV) infection and the development of cervical cancer is well documented. Cervical cancer screening guidelines are currently in the review process for updates. On May 15, 2024, the U.S. Food and Drug Administration (FDA) approved patient-collected testing (vaginal self-collection) for HPV. Several countries, including the Netherlands and Australia, have introduced HPV self-collection as a part of their national screening programs.